Condition: Recurrent Atypical/malignant Meningioma · Sponsor: Beijing Sanbo Brain Hospital
Apatinib mesylate may be an effective treatment for recurrent atypical/malignant meningioma. This prospective clinical study is now planned to verify the effectiveness and safety of apatinib mesylate in the treatment of relapsed atypical/malignant meningioma.
This description comes directly from the study's public registry record.
Jun-ping Zhang, Chief Physician · 86-010-62856783 · doczhjp@hotmail.com
Always discuss trial participation with your own doctor first.
| Sanbo Brain Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04501705